VivoSeq
Infectious Disease

Bacterial Disease

46

Pipeline Programs↗

0

Active Trials↗

22

Companies Involved↗

Bacterial Disease is a moderately active landscape with 46 programs across 22 companies. The most active players are Novartis, Triax, AbbVie. 40 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

0/100

Mech. Concentration

31/100

Completion Rate

75/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2T

Triax

1 program

Phase 2AbbVie logo

AbbVie

2 programs

ApprovedSanofi logo

Sanofi

2 programs

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

2 programs

ApprovedBayer logo

Bayer

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Terminated1 · 25%

Clinical Trials

Trial Activity

Pharmacokinetic Study of Minocycline in Patients With Pulmonary Nontuberculous Mycobacterial Disease
Terminated·RRadboud University Medical Center·Phase 2·NCT05861258·12 enrolled
Linezolid for Treatment of Nontuberculous Mycobacterial Diseases
Completed·MMahidol University·Phase 4·NCT03220074·40 enrolled
Pharmacokinetic Study With a Loading Dose of Clofazimine in Adult Patients With Nontuberculous Mycobacterial Disease
Completed·RRadboud University Medical Center·Phase 2·NCT05294146·12 enrolled
A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy
Completed·Pfizer logoPfizer·N/A·NCT00002085

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)